Premium
P2‐068: Rational Design of APOE4 Mutants as a Tool for Cellular Studies in Alzheimer’s Disease
Author(s) -
Williams Benfeard,
Convertino Marino,
Das Jhuma,
Dokholyan Nikolay V.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1273
Subject(s) - mutant , amyloid (mycology) , rational design , mutant protein , computational biology , protein structure , mutation , molecular dynamics , drug discovery , protein folding , biology , chemistry , bioinformatics , genetics , biochemistry , computational chemistry , gene , botany
to 11.37% [11.37%-14.45%] (median-IQR; p<0.05) before the last PE; while untreated group did not show any change. This effect was associated with the treatment intensity and, interestingly, correlated with Ab mobilization observed in plasma after TPE in the same Phase II study (r1⁄40.6022; p<0.0001). Conclusions:Albumin from AD patients is impaired, at least in its antioxidant capacity, in comparison with healthy subjects. TPE with albumin replacement in AD patients seems to have an effect on albumin oxidation status that correlates with plasma Ab mobilization. Further investigation is warranted to better understand the mechanisms underlying AD therapy based on TPE followed by albumin replacement.